profit from every $100 of sales.
$0$100
Tilray Brands
$2.61-1.51% today
-79.8% in 1 year
1-year low $2.531-year high $13.94
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Tilray Brands sold, what it kept, and what it did with the cash.
Sales went from $628 million in 2022 to $821 million in 2025, with -$2.19 billion of profit last year.
SalesProfit
Tilray Brands vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tilray Brands | No profit yet | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Tilray Brands's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 628 | 627 | 789 | 821 | |
| 117 | 147 | 223 | 241 | |
| -233 | -178 | -113 | -108 | |
| -246 | -1,273 | -73 | -2,128 | |
| -477 | -1,453 | -245 | -2,187 | |
| -9.00 | -23.50 | -3.30 | -24.60 | |
| 18.6% | 23.4% | 28.3% | 29.3% | |
| -37.1% | -28.4% | -14.3% | -13.1% | |
| -75.9% | -231.6% | -31.1% | -266.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5,450 | 4,307 | 4,222 | 2,074 |
| Cash | 416 | 207 | 228 | 222 |
| Total debt | 624 | 590 | 387 | 329 |
| Total liabilities | 1,008 | 977 | 778 | 585 |
| 4,399 | 3,316 | 3,443 | 1,511 | |
| 48 | 61 | 67 | 89 | |
| -6.3% | -28.4% | -4.1% | -97.1% | |
| -10.8% | -43.8% | -7.1% | -144.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -177 | 8 | -31 | -95 | |
| 34 | 21 | 29 | 33 | |
| -211 | -13 | -60 | -128 | |
| Dividends paid | – | – | – | – |
| 9 | 1 | 0 | 0 | |
| 36 | 40 | 32 | 24 |
Valuation
- –
- –
- –
- 0.4×
- 0.5×
- –
- –
- -33.1%
- -566.9%
- 0.0%
Profitability
- 29.3%
- -13.1%
- -266.3%
- -155.9%
- -100.9%
- -36.0%
- -92.8%
- -89.0%
- -112.1%
- 0.0%
Growth
- +9.3%
- –
- −113.5%
- –
- +34.8%
Financial health
- –
- 0.20
- 15.3%
- -70.4×
- 2.79
- 1.66
- 0.57
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 13%of 889
Bottom 45%of 890
Bottom 1%of 987
What analysts expect
- Average price target
- $10.00
- Range
- $10.00 – $10.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 1, 2026 | -0.24 | -0.14 | −71.4% |
| Jan 8, 2026 | -0.41 | -0.14 | −192.9% |
| Oct 9, 2025 | -0.00 | -0.27 | +98.4% |
| Jul 28, 2025 | 0.02 | -0.03 | +166.7% |
| Apr 8, 2025 | -0.10 | -0.04 | −150.0% |
| Jan 10, 2025 | -0.10 | -0.04 | −150.0% |
| Oct 10, 2024 | -0.04 | -0.04 | −11.1% |
| Jul 29, 2024 | -0.04 | -0.02 | −81.8% |
News
Does Marijuana Rescheduling Really Help Tilray's Stock?Yahoo Finance · Nov 10, 2026Tilray Just Posted Record Quarterly Revenue of $257 Million. So Why Did Its Cannabis Sales Shrink?Yahoo Finance · Nov 1, 2026Tilray reaffirms FY2027 adjusted EBITDA guidance of $68M-$75M while integrating BrewDog and preparing for Carlsberg dealSeeking Alpha · Oct 8, 2026Tilray Is Down 57% in 2026. Here's What History Says About Buying Pot Stocks at the BottomYahoo Finance · Oct 2, 2026Will Tilray Brands Stock Take Off Before the End of 2026?Yahoo Finance · Sep 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
16No pass
Benjamin Graham
75Pass
Philip Fisher
19No pass
Peter Lynch
43No pass
Joel Greenblatt
0No pass
Charlie Munger
22No pass
Terry Smith
22No pass
Questions about Tilray Brands
Is Tilray Brands a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tilray Brands AI analysis
What does Tilray Brands do?
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. It is in Drug Manufacturers - Specialty & Generic.
Does Tilray Brands pay a dividend?
No. Tilray Brands does not pay a dividend at the moment.
Is Tilray Brands stock halal?
No. Tilray Brands does not pass our halal screen: more than 5% of its revenue comes from impermissible activities. How we check
How has Tilray Brands stock done over the past year?
Down 79.8% over the past twelve months, to $2.61. It traded between $2.53 and $13.94 and is 81.3% below its high.
Who are Tilray Brands's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Tilray Brands's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.